Entvin AI has launched out of beta and announced its funding from Y Combinator. The company provides specialised Artificial Intelligence (AI) solutions for pharmaceutical and life sciences companies worldwide. The company has raised $500K in the first round of funding with a rigorous 0.1 per cent acceptance rate. With this funding, Entvin plans to expand its AI capabilities and accelerate customer acquisition among mid-to-large pharmaceutical companies globally.
With the FDA drug approval process often taking years and costing millions, any inefficiency can impact a company’s bottom line and delay life-saving treatments from reaching patients. Entvin AI is addressing this critical challenge head-on with their AI platform designed for regulatory teams.
Entvin’s AI platform targets this bottleneck by automating document drafting, compliance verification and regulatory monitoring tasks that traditionally consume thousands of hours of professional time. The platform’s technical architecture leverages large language models specifically finetuned for regulatory documentation and FDA compliance requirements. Early users report significant efficiency gains, with some teams reclaiming hundreds of hours previously spent on manual regulatory work.
Sanskar Jain, Co-Founder and CEO, Entvin, highlighted, “We identified a significant opportunity to transform how life sciences companies navigate regulatory requirements. Regulatory professionals spend countless hours on documentation, compliance check and staying updated with constantly evolving FDA guidelines. Our AI agents streamline these workflows, allowing teams to focus on strategic priorities rather than administrative burdens.”
The company, founded by Sanskar Jain, Hemant Phalak and Rishabh Arya, has developed an AI platform that streamlines the notoriously time-consuming, resource-intensive and complex FDA drug approval process, a market opportunity potentially worth billions as pharmaceutical companies worldwide seek to accelerate regulatory timelines and reduce compliance costs.
Hemant Phalak, Co-Founder and CPO, emphasised, “At Entvin, our AI agents integrate into existing workflows to enhance efficiency and accelerate decision-making. Our platform doesn’t just organise information – it identifies compliance gaps, automates repetitive documentation tasks and provides regulatory teams with actionable insights in real-time. This helps life science companies to navigate the approval process with unprecedented efficiency while maintaining trust, reliability and integration.
The company reports early success with enterprise pilot customers, demonstrating that its AI solution can save hundreds of hours for regulatory and scientific teams while improving compliance accuracy, a critical factor in an industry where regulatory missteps can cost millions.
Rishabh Arya, Co-Founder and CTO, Entvin, explained, “We’ve developed an AI system that understands the complex language of FDA regulations and can process massive volumes of regulatory documentation. Our architecture is enterprise-grade, designed to meet the highest compliance standards required by pharmaceutical companies like SOC 2, ISO 2700.”
Send news announcements/press releases to:
info@thefoundermedia.com
